Cargando…
Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy
Background and Objectives: Subclinical atherosclerosis, reflected by abnormal carotid intima–media thickness (cIMT), is pervasive among chronic kidney disease patients on chronic renal replacement therapy (RRT), being mostly influenced by uremia-related rather than traditional risk factors. Material...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319800/ https://www.ncbi.nlm.nih.gov/pubmed/35888609 http://dx.doi.org/10.3390/medicina58070890 |
_version_ | 1784755638238183424 |
---|---|
author | Bolignano, Davide Greco, Marta Arcidiacono, Valentina Presta, Pierangela Caglioti, Alfredo Andreucci, Michele Dragone, Francesco Foti, Daniela Patrizia Coppolino, Giuseppe |
author_facet | Bolignano, Davide Greco, Marta Arcidiacono, Valentina Presta, Pierangela Caglioti, Alfredo Andreucci, Michele Dragone, Francesco Foti, Daniela Patrizia Coppolino, Giuseppe |
author_sort | Bolignano, Davide |
collection | PubMed |
description | Background and Objectives: Subclinical atherosclerosis, reflected by abnormal carotid intima–media thickness (cIMT), is pervasive among chronic kidney disease patients on chronic renal replacement therapy (RRT), being mostly influenced by uremia-related rather than traditional risk factors. Materials and Methods: In this pilot study, we measured circulating levels of Omentin-1, a recently discovered adipokine with strong anti-atherogenic properties, in a heterogeneous cohort of 77 asymptomatic RRT individuals (40 chronic kidney transplant recipients, Ktx; and 37 chronic hemodialysis patients, HD) and in 30 age-matched controls. Results: Omentin-1 was increased in RRT individuals as compared with controls (p = 0.03). When stratifying for renal replacement modality, we found Ktx patients to have significantly lower Omentin-1 than HD patients (p = 0.01). Lower Omentin-1 levels were also found among RRT individuals with pathological cIMT (168.7 [51.1–457.8] vs. 474.9 [197.2–1432.1]; p = 0.004). Our multivariate correlations analysis revealed Omentin-1 as the most robust independent predictor of carotid atherosclerosis (β-0.687; p = 0.03), even more than total cholesterol, diastolic BP and age, and this adipokine was at the crossroad of a complex interplay with sustained inflammation (high CRP and ferritin) and hyperphosphatemia in predicting higher cIMT values. Conclusion: The findings reported extend to renal patients with advanced disease, with the possible involvement of Omentin-1 in the pathogenesis of atherosclerosis. This may set the stage for future interventional studies of Omentin-1 replacement to retard atherosclerosis progression, as it is currently being investigated in other disease settings. |
format | Online Article Text |
id | pubmed-9319800 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93198002022-07-27 Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy Bolignano, Davide Greco, Marta Arcidiacono, Valentina Presta, Pierangela Caglioti, Alfredo Andreucci, Michele Dragone, Francesco Foti, Daniela Patrizia Coppolino, Giuseppe Medicina (Kaunas) Brief Report Background and Objectives: Subclinical atherosclerosis, reflected by abnormal carotid intima–media thickness (cIMT), is pervasive among chronic kidney disease patients on chronic renal replacement therapy (RRT), being mostly influenced by uremia-related rather than traditional risk factors. Materials and Methods: In this pilot study, we measured circulating levels of Omentin-1, a recently discovered adipokine with strong anti-atherogenic properties, in a heterogeneous cohort of 77 asymptomatic RRT individuals (40 chronic kidney transplant recipients, Ktx; and 37 chronic hemodialysis patients, HD) and in 30 age-matched controls. Results: Omentin-1 was increased in RRT individuals as compared with controls (p = 0.03). When stratifying for renal replacement modality, we found Ktx patients to have significantly lower Omentin-1 than HD patients (p = 0.01). Lower Omentin-1 levels were also found among RRT individuals with pathological cIMT (168.7 [51.1–457.8] vs. 474.9 [197.2–1432.1]; p = 0.004). Our multivariate correlations analysis revealed Omentin-1 as the most robust independent predictor of carotid atherosclerosis (β-0.687; p = 0.03), even more than total cholesterol, diastolic BP and age, and this adipokine was at the crossroad of a complex interplay with sustained inflammation (high CRP and ferritin) and hyperphosphatemia in predicting higher cIMT values. Conclusion: The findings reported extend to renal patients with advanced disease, with the possible involvement of Omentin-1 in the pathogenesis of atherosclerosis. This may set the stage for future interventional studies of Omentin-1 replacement to retard atherosclerosis progression, as it is currently being investigated in other disease settings. MDPI 2022-07-02 /pmc/articles/PMC9319800/ /pubmed/35888609 http://dx.doi.org/10.3390/medicina58070890 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Bolignano, Davide Greco, Marta Arcidiacono, Valentina Presta, Pierangela Caglioti, Alfredo Andreucci, Michele Dragone, Francesco Foti, Daniela Patrizia Coppolino, Giuseppe Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy |
title | Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy |
title_full | Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy |
title_fullStr | Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy |
title_full_unstemmed | Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy |
title_short | Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy |
title_sort | circulating omentin-1, sustained inflammation and hyperphosphatemia at the interface of subclinical atherosclerosis in chronic kidney disease patients on chronic renal replacement therapy |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319800/ https://www.ncbi.nlm.nih.gov/pubmed/35888609 http://dx.doi.org/10.3390/medicina58070890 |
work_keys_str_mv | AT bolignanodavide circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy AT grecomarta circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy AT arcidiaconovalentina circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy AT prestapierangela circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy AT cagliotialfredo circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy AT andreuccimichele circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy AT dragonefrancesco circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy AT fotidanielapatrizia circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy AT coppolinogiuseppe circulatingomentin1sustainedinflammationandhyperphosphatemiaattheinterfaceofsubclinicalatherosclerosisinchronickidneydiseasepatientsonchronicrenalreplacementtherapy |